News

Featured News

  • Categories: News | Published On: December 18, 2023 |

    Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors

  • Categories: News | Published On: December 14, 2023 |

    Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

  • Categories: News | Published On: August 23, 2022 |

    The Logical Song: Biolojic Design Reimagines Antibodies into “Smart” Therapeutics

Filter by:
  • Categories: News | Published On: April 5, 2022 |

    First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients

  • Categories: News | Published On: March 8, 2021 |

    Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes

  • Categories: News | Published On: February 25, 2021 |

    Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against a Novel Target for the Potential Treatment of Autoimmune Disease

  • Categories: Publication | Published On: February 21, 2021 |

    Biolojic’s anti IL2 antibody covered in Nature’s review of current IL2 therapies in development

  • Categories: News | Published On: January 8, 2021 |

    ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer

  • Categories: Publication | Published On: January 5, 2019 |

    Computational Design of Antibodies

  • Categories: Publication | Published On: November 20, 2018 |

    Computational Design of Epitope-Specific Functional Antibodies